Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors

Ivosidenib, an inhibitor of isocitrate dehydrogenase 1 (IDH1) R132C and R132H variants, is approved for the treatment of acute myeloid leukaemia (AML). Resistance to ivosidenib due to a second site mutation of IDH1 R132C, leading to IDH1 R132C/S280F, has emerged. We describe biochemical, crystallogr...

Полное описание

Библиографические подробности
Главные авторы:	Reinbold, R, Hvinden, IC, Rabe, P, Herold, RA, Finch, A, Wood, J, Morgan, M, Staudt, M, Clifton, IJ, Armstrong, FA, McCullagh, JSO, Redmond, J, Bardella, C, Abboud, MI, Schofield, CJ
Формат:	Journal article
Язык:	English
Опубликовано:	Springer Nature 2022

Схожие документы

Resistance to the isocitrate dehydrogenase 1 mutant inhibitor ivosidenib can be overcome by alternative dimer-interface binding inhibitors
по: Raphael Reinbold, и др.
Опубликовано: (2022-08-01)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
по: Hvinden, IC, и др.
Опубликовано: (2021)

Isocitrate dehydrogenase gene variants in cancer and their clinical significance
по: Cadoux-Hudson, T, и др.
Опубликовано: (2021)

Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1
по: Liu, S, и др.
Опубликовано: (2021)

Differentiating inhibition selectivity and binding affinity of isocitrate dehydrogenase 1 variant inhibitors
по: Liu, S, и др.
Опубликовано: (2023)

Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
по: DiNardo, CD, и др.
Опубликовано: (2020)

Exploiting electrode nanoconfinement to investigate the catalytic properties of isocitrate dehydrogenase (IDH1) and a cancer-associated variant
по: Herold, RA, и др.
Опубликовано: (2021)

Exploring metabolic vulnerability and therapeutic potential in cancers with isocitrate dehydrogenase mutations
по: Hvinden, IC
Опубликовано: (2022)

Natural and synthetic 2-oxoglutarate derivatives are substrates for oncogenic variants of human isocitrate dehydrogenase 1 and 2
по: Liu, X, и др.
Опубликовано: (2023)

Anion-exchange chromatography mass spectrometry provides extensive coverage of primary metabolic pathways revealing altered metabolism in IDH1 mutant cells
по: Walsby-Tickle, J, и др.
Опубликовано: (2020)

Roles of metal ions in the selective inhibition of oncogenic variants of isocitrate dehydrogenase 1
по: Shuang Liu, и др.
Опубликовано: (2021-11-01)

Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study
по: Mingyuan Sun, и др.
Опубликовано: (2024-07-01)

Electrochemical nanoreactor provides a comprehensive view of isocitrate dehydrogenase cancer-drug kinetics
по: Herold, RA, и др.
Опубликовано: (2023)

Studies on human cancer variant and mycobacterial isocitrate dehydrogenases
по: Reinbold, R
Опубликовано: (2021)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
по: Xiaoyan Liu, и др.
Опубликовано: (2019-10-01)

Inhibitors of mutant isocitrate dehydrogenase for isocitrate dehydrogenase-mutant gliomas: A new standard of care?
по: Emilie Le Rhun, и др.
Опубликовано: (2024-01-01)

Isocitrate Dehydrogenase Inhibitors in Glioma: From Bench to Bedside
по: Merve Hazal Ser, и др.
Опубликовано: (2024-05-01)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
по: Yang Liu, и др.
Опубликовано: (2023-04-01)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
по: Danielle Golub, и др.
Опубликовано: (2019-05-01)

Editorial overview: recent advances in metabolomics
по: McCullagh, JSO, и др.
Опубликовано: (2024)

Preparative HPLC separation of underivatized amino acids for isotopic analysis
по: Tripp, JA, и др.
Опубликовано: (2019)

Functional relevance of dynamic properties of Dimeric NADP-dependent Isocitrate Dehydrogenases
по: Vinekar Rithvik, и др.
Опубликовано: (2012-12-01)

Polyphenols: bioavailability, microbiome interactions and cellular effects on health in humans and animals
по: Scott, MB, и др.
Опубликовано: (2022)

The IDH1 inhibitor ivosidenib improved seizures in a patient with drug-resistant epilepsy from IDH1 mutant oligodendroglioma
по: Anh Huan Vo, и др.
Опубликовано: (2022-01-01)

Screening For Potential Inhibitors Of Mycobacterium Tuberculosis Isocitrate Lyase: In Silico And In Vitro Approaches
по: Lee , Yie Vern
Опубликовано: (2017)

Discovery of a Novel Inhibitor Structure of <i>Mycobacterium tuberculosis</i> Isocitrate Lyase
по: Changyuan Duan, и др.
Опубликовано: (2022-04-01)

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat
по: Chi-Ming Chang, и др.
Опубликовано: (2023-05-01)

Identification of Mannich Base as a Novel Inhibitor of Mycobacterium Tuberculosis Isocitrate by High-Throughput Screening
по: Lei Ji, Quanxin Long, Dacheng Yang, Jianping Xie
Опубликовано: (2011-01-01)

NADP(H)-dependent biocatalysis without adding NADP(H)
по: Herold, RA, и др.
Опубликовано: (2022)

The broad spectrum 2-oxoglutarate oxygenase inhibitor N-oxalylglycine is present in rhubarb and spinach leaves
по: Al-Qahtani, K, и др.
Опубликовано: (2015)

Species identification of silks by protein mass spectrometry reveals evidence of wild silk use in antiquity
по: Lee, B, и др.
Опубликовано: (2022)

Ivosidenib, an IDH1 inhibitor, in a patient with recurrent, IDH1-mutant glioblastoma: a case report from a Phase I study
по: Dalissa Tejera, и др.
Опубликовано: (2020-09-01)

Isocitrate dehydrogenase variants in cancer — Cellular consequences and therapeutic opportunities
по: Liu, S, и др.
Опубликовано: (2020)

Inhibitors of BRAF dimers using an allosteric site
по: Xiomaris M. Cotto-Rios, и др.
Опубликовано: (2020-09-01)

Conservation of the unusual dimeric JmjC fold of JMJD7 from Drosophila melanogaster to humans
по: Chowdhury, R, и др.
Опубликовано: (2022)

Safety and Clinical Activity of Mutant IDH1 Inhibitor IVOSIDENIB (IVO; AG-120) In Combination with AZACITIDINE (AZA) for Newly Diagnosed Acute Myeloid Leukemia (ND AML)
по: DiNardo, C, и др.
Опубликовано: (2019)

Aldehyde-mediated inhibition of asparagine biosynthesis has implications for diabetes and alcoholism
по: John, T, и др.
Опубликовано: (2024)

P441: CLINICAL AND MOLECULAR CHARACTERISTICS OF AML PATIENTS WITH AN EXCEPTIONAL RESPONSE TO IVOSIDENIB
по: Justin M. Watts, и др.
Опубликовано: (2023-08-01)

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
по: Uson Junior PLS, и др.
Опубликовано: (2023-09-01)

Interferon-stimulated gene products as regulators of central carbon metabolism
по: Honarmand Ebrahimi, K, и др.
Опубликовано: (2020)